Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Medical Management of Peyronie’s Disease: a 2014 Update

Medical Management of Peyronie’s Disease: a 2014 Update Peyronie’s disease (PD) is a connective tissue disorder characterized by the development of dense fibrous collagen plaque deposits in the tunica albuginea of the penis, resulting in curvature of the erection and sexual dysfunction. It is both a physically and psychologically devastating disorder that remains a considerable therapeutic dilemma due to incomplete characterization of its pathophysiology and the paucity of randomized controlled trials. Along with an underlying genetic predisposition, numerous studies have implicated pro-inflammatory cascades and oxidative stress in the development of PD. Medical therapies targeting these pathways can be partially effective at decreasing or inhibiting plaque formation and symptoms of PD. Such therapies include the broad categories of oral medication and vitamin supplements, intralesional injections, and penile traction. The recent FDA approval for intralesional collagenase clostridium histolyticum provides a significant advancement in the medical treatment of PD. In addition to highlighting the latest data supporting intralesional collagenase clostridium histolyticum, this update aims to review the most current literature on all of the available options for medical treatment of PD and to provide a practical approach to the clinical management of PD in the office setting. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Sexual Health Reports Springer Journals

Medical Management of Peyronie’s Disease: a 2014 Update

Loading next page...
 
/lp/springer-journals/medical-management-of-peyronie-s-disease-a-2014-update-TEXE37g3eS
Publisher
Springer Journals
Copyright
Copyright © 2014 by Springer Science+Business Media, LLC
Subject
Medicine & Public Health; Urology/Andrology; Endocrinology
ISSN
1548-3584
eISSN
1548-3592
DOI
10.1007/s11930-014-0021-y
Publisher site
See Article on Publisher Site

Abstract

Peyronie’s disease (PD) is a connective tissue disorder characterized by the development of dense fibrous collagen plaque deposits in the tunica albuginea of the penis, resulting in curvature of the erection and sexual dysfunction. It is both a physically and psychologically devastating disorder that remains a considerable therapeutic dilemma due to incomplete characterization of its pathophysiology and the paucity of randomized controlled trials. Along with an underlying genetic predisposition, numerous studies have implicated pro-inflammatory cascades and oxidative stress in the development of PD. Medical therapies targeting these pathways can be partially effective at decreasing or inhibiting plaque formation and symptoms of PD. Such therapies include the broad categories of oral medication and vitamin supplements, intralesional injections, and penile traction. The recent FDA approval for intralesional collagenase clostridium histolyticum provides a significant advancement in the medical treatment of PD. In addition to highlighting the latest data supporting intralesional collagenase clostridium histolyticum, this update aims to review the most current literature on all of the available options for medical treatment of PD and to provide a practical approach to the clinical management of PD in the office setting.

Journal

Current Sexual Health ReportsSpringer Journals

Published: Apr 16, 2014

There are no references for this article.